Grundläggande statistik
| LEI | 5299002XZU0SNKHPUS06 |
| CIK | 1213660 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to BIMI Holdings Inc.
SEC Filings (Chronological Order)
Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.
| July 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2024 BIMI Holdings Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) (Commission File N |
|
| June 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2024 BIMI Holdings Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| May 29, 2024 |
May 29, 2024 Nasreen Mohammed Adam Phippen Taylor Beech Mara Ransom United States Securities and Exchange Commission Washington, D. |
|
| May 24, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2024 BIMI Holdings Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| May 24, 2024 |
Exhibit 10.1 Debt conversion AGREEMENT between BIMI HOLDINGS INC. and FNU OUDOM dated as of May 21, 2024 DEBT CONVERSION AGREEMENT This Debt Conversion Agreement (this “Agreement”), dated as of May 21, 2024, is entered into by and between BIMI HOLDINGS INC., a Delaware corporation (the “Company”), and Fnu Oudom, a citizen of Vanuatu (the “Lender”). RECITALS WHEREAS, the Company wishes to convert a |
|
| May 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2024 BIMI Holdings Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| May 20, 2024 |
BIMI Announces Receipt of a Delinquency Compliance Alert Notice from Nasdaq Exhibit 99.1 BIMI Announces Receipt of a Delinquency Compliance Alert Notice from Nasdaq New York, May 20, 2024 (GLOBE NEWSWIRE) — BIMI Holdings Inc. (NASDAQ: BIMI) (“BIMI” or the “Company”), previously known as BIMI International Medical Inc., a healthcare products and services provider, today announced that on May 17, 2024, it received a delinquency compliance alert notice from the Listing Quali |
|
| May 8, 2024 |
BIMI INTERNATIONAL MEDICAL, INC. AND ITS SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS May 7 , 2024 Nasreen Mohammed Adam Phippen Taylor Beech Mara Ransom United States Securities and Exchange Commission Washington, D. |
|
| April 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2024 BIMI Holdings Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) (Commission File |
|
| April 23, 2024 |
BIMI Announces Receipt of a Delinquency Compliance Alert Notice from Nasdaq Exhibit 99.1 BIMI Announces Receipt of a Delinquency Compliance Alert Notice from Nasdaq New York, April 23, 2024 (GLOBE NEWSWIRE) — BIMI Holdings Inc. (NASDAQ: BIMI) (“BIMI” or the “Company”), previously known as BIMI International Medical Inc., a healthcare products and services provider, today announced that on April 19, 2024, it received a delinquency compliance alert notice from the Listing Q |
|
| April 2, 2024 |
SEC FILE NUMBER: 001-34890 CUSIP NUMBER: 05552Q301 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2024 BIMI Holdings Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) (Commission File |
|
| February 7, 2024 |
February 7, 2024 Nasreen Mohammed Adam Phippen Taylor Beech Mara Ransom United States Securities and Exchange Commission Washington, D. |
|
| January 11, 2024 |
SC 13D/A 1 ea191437-13da2oudombimi.htm AMENDMENT NO. 2 TO SCHEDULE 13D SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Amendment No. 2 (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13D-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13D-2(a) BIMI Holdings Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 05552Q202 (CUSIP Nu |
|
| January 11, 2024 |
EX-4.1 2 ea191437ex4-1bimiinter.htm CVI SHARE PURCHASE AGREEMENT NOVEMBER 27, 2023 Exhibit 4.1 Execution Version SHARE PURCHASE AGREEMENT This Share Purchase Agreement (the “Agreement”), dated as of November 27, 2023 is by and between CVI Investments, Inc. (the “Seller”) and Mr. Fnu Oudom (the “Buyer”). W I T N E S S E T H: WHEREAS, the Seller owns 214,044 shares of restricted common stock of BIMI |
|
| January 11, 2024 |
EX-4.2 3 ea191437ex4-2bimiinter.htm HUDSON BAY SHARE PURCHASE AGREEMENT NOVEMBER 27, 2023 Exhibit 4.2 Execution Version SHARE PURCHASE AGREEMENT This Share Purchase Agreement (the “Agreement”), dated as of November 27, 2023 is by and between Hudson Bay Master Fund Ltd. (the “Seller”) and Mr. Fnu Oudom (the “Buyer”). W I T N E S S E T H: WHEREAS, the Seller owns 200,000 shares of restricted common |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2024 BIMI Holdings Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) (Commission File |
|
| January 8, 2024 |
CERTIFICATE OF AMENDMENT TO THE amended and restated BYLAWS BIMI INTERNATIONAL MEDICAL INC. Exhibit 3.2 CERTIFICATE OF AMENDMENT TO THE amended and restated BYLAWS OF BIMI INTERNATIONAL MEDICAL INC. BIMI INTERNATIONAL MEDICAL INC. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies as follows: FIRST: Each of Sections 3.02, 3.03, 3.04 and 3.05 of the Amended and Restated Bylaws |
|
| January 8, 2024 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE amended and restated certificate of incorporation OF BIMI INTERNATIONAL MEDICAL INC. BIMI INTERNATIONAL MEDICAL INC. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies as follows: FIRST: Article 1 of the Amended and Restated Certificate of In |
|
| January 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2024 BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) (Co |
|
| January 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2024 BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) (Co |
|
| January 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2023 BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) ( |
|
| January 3, 2024 |
BIMI Announces Results of 2023 Annual General Meeting of Stockholders Exhibit 99.1 BIMI Announces Results of 2023 Annual General Meeting of Stockholders New York, January 3rd, 2024 — BIMI International Medical Inc. (NASDAQ: BIMI) (“BIMI” or the “Company”), a healthcare products and services provider, today announced the results of the Company’s 2022 Annual General Meeting of Stockholders (the “Annual Meeting”) held on Dec 29, 2023 at 11:00 a.m. at the offices of the |
|
| December 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2023 BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) ( |
|
| December 19, 2023 |
BIMI International Medical Inc. Announces Third Quarter 2023 Financial Results Exhibit 99.1 BIMI International Medical Inc. Announces Third Quarter 2023 Financial Results NEW YORK, Dec. 19, 2023 — BIMI International Medical Inc. (the “Company”), a leading medical solutions provider, today announced its financial results for the three months and nine months ended September 30, 2023. Revenues for the three months ended September 30, 2023 and 2022 were $2,523,193 and $4,932,479 |
|
| December 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50155 BIMI Internation |
|
| December 19, 2023 |
SC 13D/A 1 ea190271-13da1oudombimi.htm AMENDMENT NO. 1 TO SCHEDULE 13D SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Amendment No. 1 (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13D-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13D-2(a) BIMI International Medical Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 05552Q |
|
| December 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2) ☒ Definitive Proxy Statem |
|
| December 11, 2023 |
Unregistered Sales of Equity Securities, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2023 BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) (C |
|
| December 6, 2023 |
Shareholder Director Nominations UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2023 BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) (C |
|
| December 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2) ☐ Definitive Proxy Statem |
|
| December 4, 2023 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2023 BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) ( |
|
| December 4, 2023 |
Consent Letter of Audit Alliance LLP dated December 4, 2023 Exhibit 16.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We have read the statements under Item 4.01 in the Current Report on Form 8-K dated December 4, 2023 (the “8-K”), of BIMI International Medical Inc (the “Company”) to be filed with the Securities and Exchange Commission and we agree with such statements therein as related to our firm. We have no basis, and therefore, do not agre |
|
| December 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 27, 2023 BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) ( |
|
| December 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 27, 2023 BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) ( |
|
| November 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 27, 2023 BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) ( |
|
| November 28, 2023 |
Form of Warrant Purchase Agreements Exhibit 4.1 WARRANT PURCHASE AGREEMENT This Warrant Purchase Agreement (the “Agreement”), dated as of November 24, 2023, is by and between BIMI International Medical Inc. (the “Buyer” or the “Company”) and (the “Seller” and together with the Buyer, each individually a “Party” and collectively the “Parties”). WITNESSETH: WHEREAS, the Seller owns certain warrants to purchase shares of common stock o |
|
| November 28, 2023 |
BIMI Announces Buyback of Warrants Exhibit 99.1 BIMI Announces Buyback of Warrants NEW YORK, NY, Nov. 28, 2023 (GLOBE NEWSWIRE) - BIMI International Medical Inc. (NASDAQ: BIMI, “BIMI”), a healthcare products and services provider, today announced its entry into material definitive agreements with certain of its warrant holders, pursuant to which BIMI agreed to buy back an aggregate of 7,066,913 warrants to purchase shares of common |
|
| November 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2023 BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) ( |
|
| November 27, 2023 |
BIMI International Medical Inc. Announces Second Quarter 2023 Financial Results Exhibit 99.1 BIMI International Medical Inc. Announces Second Quarter 2023 Financial Results NEW YORK, November 27, 2023 — BIMI International Medical Inc. (the “Company”), a leading medical solutions provider, today announced its financial results for the three months ended June 30, 2023. The Company reported a significant increase in gross margin underlining the ongoing success of its business st |
|
| November 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2023 BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) ( |
|
| November 27, 2023 |
BIMI Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1) Exhibit 99.1 BIMI Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1) NEW YORK, November 27, 2023 - BIMI International Medical Inc. (the “Company”) today announced that on November 21, 2023, the Company received a notification letter from The Nasdaq Stock Market LLC (“Nasdaq”) stating that, because the Company has not yet filed its Quarterly Report on Form 10-Q for the peri |
|
| November 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50155 BIMI International Me |
|
| November 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: September 30, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| November 8, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2023 BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) (C |
|
| November 8, 2023 |
BIMI Announces Subsidiary Phenix Bio Inc.’s New Product Launch Exhibit 99.1 BIMI Announces Subsidiary Phenix Bio Inc.’s New Product Launch NEW YORK, NY, Nov. 08, 2023 (GLOBE NEWSWIRE) - Phenix Bio Inc., a wholly owned subsidiary of BIMI International Medical Inc. (NASDAQ: BIMI), a leading global healthcare provider, announces the official launch of its "CUCA 3.0 Product Line through China Duty Free Group's (CDFG) online mini program sales platform. This signi |
|
| October 30, 2023 |
BIMI International Medical Inc. Announces Subsidiary Phenix Bio Inc Exhibit 99.2 BIMI International Medical Inc. Announces Subsidiary Phenix Bio Inc’s Appointment of Hong Kong, Taiwan, and Macau Exclusive Distributor NEW YORK, NY, Oct. 30, 2023 — BIMI International Medical Inc. (NASDAQ: BIMI, “BIMI”), a healthcare products and services provider today announced that its subsidiary, Phenix Bio Inc., appointed Hao Mu Pte. Ltd., a Singapore company (“Hao Mu”), as its |
|
| October 30, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2023 BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) (C |
|
| October 30, 2023 |
BIMI International Medical Inc. Announces Subsidiary Phenix Bio Inc Exhibit 99.1 BIMI International Medical Inc. Announces Subsidiary Phenix Bio Inc’s Appointment of Mainland China Non-Exclusive Distributor NEW YORK, NY, Oct. 30, 2023 (GLOBE NEWSWIRE) - BIMI International Medical Inc. (NASDAQ: BIMI, “BIMI”), a healthcare products and services provider today announced that its subsidiary, Phenix Bio Inc., appointed Hao Mu Pte. Ltd., a Singapore company (“Hao Mu”), |
|
| September 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2023 BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) |
|
| September 22, 2023 |
Exhibit 99.1 BIMI International Medical Inc. Announces Subsidiary Phenix Bio Inc’s Appointment of ASEAN Exclusive Distributor NEW YORK, NY, Sept. 22, 2023 (GLOBE NEWSWIRE) - BIMI International Medical Inc. (NASDAQ: BIMI, “BIMI”), a healthcare products and services provider today announced its subsidiary, Phenix Bio Inc., appointed Hao Mu Pte. Ltd., a Singapore company, as its exclusive distributor |
|
| August 24, 2023 |
BIMI Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1) Exhibit 99.1 BIMI Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1) NEW YORK, Aug. 24, 2023 (GLOBE NEWSWIRE) - BIMI International Medical Inc. (the “Company”) today announced that on August 22, 2023, the Company received a notification letter from The Nasdaq Stock Market LLC (“Nasdaq”) stating that, because the Company has not yet filed its Quarterly Report on Form 10-Q f |
|
| August 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 22, 2023 BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) (Co |
|
| August 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: June 30, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2023 BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) (Com |
|
| August 7, 2023 |
Exhibit 99.1 BIMI International Medical Inc. Announces Strategic Partnership by its Phenix Bio Inc. Subsidiary with China Duty Free Group NEW YORK, NY, Aug. 07, 2023 (GLOBE NEWSWIRE) - BIMI International Medical Inc. (NASDAQ: BIMI, “BIMI”), a leading global provider of healthcare services and innovative medical solutions, today announced the formation of a strategic partnership between its subsidi |
|
| June 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2023 BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) (Comm |
|
| May 22, 2023 |
BIMI International Medical Inc. Announces First Quarter 2023 Financial Results Exhibit 99.1 BIMI International Medical Inc. Announces First Quarter 2023 Financial Results NEW YORK, May 22, 2023 — BIMI International Medical Inc. (the “Company”), a leading medical solutions provider, today announced its financial results for the three months ended March 31, 2023. The Company reported a significant decrease in net losses and notable improvements in working capital, underlining |
|
| May 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2023 BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) (Commi |
|
| May 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50155 BIMI International M |
|
| May 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) (Commi |
|
| May 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: March 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| May 4, 2023 |
Certificate of Amendment to Certificate of Incorporation Exhibit 3.8 |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended: December 31, 2022 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 000-50155 BIMI International Medica |
|
| May 4, 2023 |
Subsidiaries of the Registrant Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT: Entity Name Place of Incorporation Effective Interests Held BIMI International Medical Inc. Delaware 100 % Bimai Pharmaceutical (Chongqing) Co., Ltd. Chongqing, China 100 % Boyi (Liaoning) Technology Co., Ltd Liaoyang, China 100 % Lasting Wisdom Holdings Limited BVI 100 % PUKUNG Limited Hong Kong, China 100 % Beijing Xinrongxin Industrial Development Co |
|
| May 4, 2023 |
Certificate of Amendment to Certificate of Incorporation Exhibit 3.6 |
|
| May 4, 2023 |
Certificate of Amendment to Amended and Restated Certificate of Incorporation Exhibit 3.10 |
|
| April 24, 2023 |
BIMI International medical inc. (NASDAQ: BIMI) BIMI International medical inc. (NASDAQ: BIMI) April 24, 2023 U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Ms. Nasreen Mohammed Re: BIMI International Medical Inc. Amendment No. 1 to Form 10-K for the Fiscal Year Ended December 31, 2021 Response dated February 23, 2023 File No.: 001-34890 Dear Ladies and Gentlemen: We are submitting this letter in respons |
|
| April 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2023 BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) (Com |
|
| April 24, 2023 |
BIMI Announces Results of 2023 Special meeting of Shareholders. Exhibit 99.1 BIMI Announces Results of 2023 Special meeting of Shareholders. NEW YORK, April 19, 2023 (GLOBE NEWSWIRE) - BIMI International Medical Inc. (NASDAQ: BIMI) (“BIMI” or the “Company”), a healthcare products and services provider, today announced the results of the Company’s 2023 Special Meeting of Shareholders held on April 13, 2023 at the offices of the Company, 15th Floor, 725 5th Aven |
|
| April 20, 2023 |
BIMI Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1) Exhibit 99.1 BIMI Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1) NEW YORK, April 20, 2023 (GLOBE NEWSWIRE) - On April 18, 2023, BIMI International Medical Inc. (the “Company”) today announced that on April 18, 2023, the Company received a notification letter from The Nasdaq Stock Market LLC (“Nasdaq”) stating that, because the Company has not yet filed its Annual Repor |
|
| April 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2023 BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) (Com |
|
| April 14, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2023 BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) (Com |
|
| April 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2022 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2023 BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) (Com |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| March 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2023 BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) ( |
|
| March 1, 2023 |
Stock Purchase Agreement dated February 27, 2023 Exhibit 4.2 STOCK PURCHASE AGREEMENT between BIMI MEDICAL INTERNATIONAL INC. and FNU OUDOM dated as of February 27, 2023 STOCK PURCHASE AGREEMENT This Stock Purchase Agreement (this “Agreement”), dated as of February 27, 2023, is entered into by and between BIMI Medical International Inc., a Delaware corporation (the “Company”), and Fnu Oudom, a citizen of Vanuatu (the “Buyer”). RECITALS WHEREAS, |
|
| March 1, 2023 |
Amendment to Stock Purchase Agreement dated February 27, 2023 Exhibit 4.1 AMENDMENT to Stock purchase AGREEMENT This Amendment to Stock Purchase Agreement (this “Agreement”) is made and entered into as of February 27, 2023 by and among BIMI INTERNATIONAL MEDICAL INC., a company organized under the laws of the state of Delaware (“Buyer”), PHENIX BIO INC., a company organized under the laws of the state of California (the “Company”) and Mr. Fnu Oudom, a citize |
|
| March 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 1, 2023 |
Prepayment Agreement dated February 27, 2023 Exhibit 4.3 Prepayment agreement This Prepayment Agreement (this “Agreement”) is made and entered into as of February 27, 2023 by and among BIMI INTERNATIONAL MEDICAL INC., a company organized under the laws of the state of Delaware (the “Company”) and Mr. Fnu Oudom, a citizen of Vanuatu (the “Holder”). Each of the parties named above may be referred to herein as a “Party” and collectively as the |
|
| February 23, 2023 |
BIMI INTERNATIONAL MEDICAL INC. (NASDAQ: BIMI) February 23, 2023 U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Ms. Nasreen Mohammed Re: BIMI International Medical Inc. Form 10-K for the Fiscal Year Ended December 31, 2021 Amendment No. 1 to Form 10-K Filed August 31, 2022 Form 10-Q for the Quarterly Period ended September 30, 2022 File No.: 001-34890 Dea |
|
| February 6, 2023 |
Pang Zhang-Whitaker Partner 28 Liberty Street [email protected] New York, NY 10005 D / 212-238-8844 February 6, 2023 Ms. Kate Beukenkamp Securities and Exchange Commission Division of Corporation Finance Office of Trade & Services Re: BIMI International Medical Inc. Form 10-K for the Fiscal Year Ended December 31, 2021 Amendment No. 1 to Form 10-K Filed August 31, 2022 Form 10-Q for the Quarterly Peri |
|
| January 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) (Co |
|
| January 4, 2023 |
Transfer Agreement dated December 28, 2022 Exhibit 4.2 transfer AGREEMENT This Transfer Agreement (this ?Agreement?), dated as of December 28, 2022, is entered into by and among BIMI INTERNATIONAL MEDICAL INC. (?BIMI?), CHAOHU ZHONGSHAN MINIMALLY INVASIVE HOSPITAL Co., Ltd., a company organized under the laws of the PRC (?Zhongshan?) and Mr. YU XIANG, a citizen of the PRC (?Xiang?). Each of the parties named above may be referred to herein |
|
| January 4, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 28, 2022 BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) ( |
|
| January 4, 2023 |
Transfer Agreement dated December 28, 2022 Exhibit 4.1 Transfer Agreement This Transfer Agreement (this ?Agreement?) is made and entered into as of December 28, 2023 by and among BIMI INTERNATIONAL MEDICAL INC., a company organized under the laws of the state of Delaware, the U.S.A. (?Parent?), BIMI PHARMACEUTICAL (CHONGQING) CO., LTD. (also known as BimAi PHARMACEUTICAL (Chongqing) Co., Ltd.), a company organized under the laws of the PRC |
|
| December 28, 2022 |
Performance Pledges dated December 23, 2022 Exhibit 4.1 performance pledgeS Tiewei Song, the Chief Executive Officer, and Xiaoping Wang, the Chief Operating Officer, of BIMI International Medical Inc., a company organized under the laws of the state of Delaware, the U.S.A. (the ?Company?), for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, hereby make the following performance pledges to the C |
|
| December 28, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2022 BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) ( |
|
| December 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2022 BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) ( |
|
| December 20, 2022 |
Termination Agreement dated December 15, 2022 Exhibit 4.1 termination Agreement This termination agreement (the “Agreement”) is made and entered into as of December 15, 2022 by and among BIMI International Medical Inc., a company organized under the laws of the state of Delaware, the U.S.A. (“Parent”), BIMI HOSPITAL MANAGEMENT (Chongqing) Co., Ltd. (formerly known as BIMAI HOSPITAL MANAGEMENT (CHONGQING) CO., LTD.) , a company organized under |
|
| December 13, 2022 |
Amendment No. 3 to Stock Purchase Agreement and Settlement Agreement dated December 9, 2022 Exhibit 4.1 AMENDMENT NO. 3 to Stock purchase AGREEMENT and settlement Agreement This Amendment No. 3 to Stock Purchase Agreement and Settlement Agreement (this “Agreement”) is made and entered into as of November 9, 2022 by and among BIMI INTERNATIONAL MEDICAL INC., a company organized under the laws of the state of Delaware, the U.S.A. (“Parent”), BIMI PHARMACEUTICAL (CHONGQING) CO., LTD. (also |
|
| December 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2022 BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) (C |
|
| December 13, 2022 |
BIMI Announces Entry into a Material Definitive Agreement Exhibit 99.1 BIMI Announces Entry into a Material Definitive Agreement NEW YORK, Dec. 13, 2022 (GLOBE NEWSWIRE) - BIMI International Medical Inc. (NASDAQ: BIMI) (“BIMI” or the “Company”), a healthcare products and services provider, today announced its entry into an Amendment to the Stock Purchase Agreement originally entered into as of April 9, 2021 (the “Amendment”) for the acquisition of Wuzhou |
|
| December 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2022 BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) (C |
|
| December 8, 2022 |
BIMI Announces Sale of $2 Million Promissory Note Exhibit 99.1 BIMI Announces Sale of $2 Million Promissory Note NEW YORK, Dec. 08, 2022 (GLOBE NEWSWIRE) - BIMI International Medical Inc. (NASDAQ: BIMI) (?BIMI? or the ?Company?), a healthcare products and services provider, today announced the sale of a $2 Million promissory note (the ?Note?) to the Chairman of the Board of the Company, Mr. Fnu Oudom on December 6, 2022. The Note carries an annua |
|
| December 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2022 BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) (C |
|
| December 8, 2022 |
Exhibit 99.1 BIMI Announces 1-for -10 Reverse Stock Split BIMI intends to use a reverse-stock split to bring the company into compliance with listing requirements of The Nasdaq Capital Market. NEW YORK, Dec. 08, 2022 (GLOBE NEWSWIRE) - BIMI International Medical Inc. (NASDAQ: BIMI) (?BIMI? or the ?Company?), a healthcare products and services provider, today announced a 1-for-10 reverse split of i |
|
| December 8, 2022 |
Convertible Promissory Note Dated December 6, 2022 Exhibit 4.1 THIS NOTE AND ANY SECURITIES ISSUABLE PURSUANT HERETO HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER THE ACT OR, SUBJECT TO THE TERMS SET FORTH IN THIS NOTE, IN THE OPINION OF COUNSEL IN FORM AND SUBSTANCE REASONABLY SATISFACTORY TO THE IS |
|
| November 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 23, 2022 BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) ( |
|
| November 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50155 BIMI Internation |
|
| November 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: September 30, 2022 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| October 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 19, 2022 BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) (C |
|
| October 24, 2022 |
Sale and Purchase Agreement dated October 19, 2022 Exhibit 4.1 SALE AND PURCHASE AGREEMENT This Sale and Purchase Agreement (this “Agreement”), dated as of October 19, 2022, is entered into by and among BIMI INTERNATIONAL MEDICAL INC. (“Parent”), CHONGQING GUANZAN TECHNOLOGY CO., LTD. (“Guanzan”), CHONGQING ZHUODA PHARMACEUTICAL CO., LTD. (“Zhuoda”), XIAOLIN LIU (“Liu”), XUSEN HE (“He”), DONG ZHANG (“Zhang”, together with Liu and He, the “Liu Grou |
|
| October 24, 2022 |
Exhibit 99.1 BIMI Enters into Definitive Agreement for the Disposal of Assets in China BIMI intends to dispose of underperforming assets in China for exploring greater prospects in the United States. New York, Oct. 24, 2022 (GLOBE NEWSWIRE) - BIMI International Medical Inc. (NASDAQ: BIMI) (“BIMI” or the “Company”), a healthcare products and services provider, today announced that it has entered in |
|
| August 31, 2022 |
August 31, 2022 Nasreen Mohammed Adam Phippen Ryan Lichtenfels Erin Jaskot United States Securities and Exchange Commission Washington, D. |
|
| August 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ? Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended: December 31, 2021 or ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 000-50155 BIMI |
|
| August 31, 2022 |
Subsidiaries of the Registrant Exhibit 21.1 Ex 21.1 Subsidiaries of the Registrant Entity Name Place of Incorporation Type of legal entity Effective interest held BIMI International Medical Inc. Delaware Public company 100 % Bimai Pharmaceutical (Chongqing) Co., Ltd. Chongqing, China Limited liability company 100 % Boyi (Liaoning) Technology Co., Ltd Liaoyang, China Limited liability company 100 % Lasting Wisdom Holdings Limite |
|
| August 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 August 22. 2022 Date of Report (Date of earliest event reported) BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 000-50155 02-0563302 (State or other jurisdiction of incorporation) (Com |
|
| August 22, 2022 |
BIMI Announces Second Quarter 2022 Financial Results Exhibit 99.1 BIMI Announces Second Quarter 2022 Financial Results New York, August 22, 2022 (GLOBE NEWSWIRE) - BIMI International Medical Inc. (NASDAQ: BIMI) (?BIMI? or the ?Company?), a healthcare products and services provider, today announced its financial results for the six months ended June 30, 2022. Revenues for the six months ended June 30, 2022 and 2021 were $9,947,109 and $11,424,991, re |
|
| August 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50155 BIMI International Me |
|
| August 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ?Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: June 30, 2022 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| August 8, 2022 |
US05552Q2021 / BIMI INTERNATIONAL MEDICAL INC / Oudom Fnu - SCHEDULE 13D Activist Investment SC 13D 1 ea163687-13doudombimi.htm SCHEDULE 13D SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13D-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13D-2(a) BIMI International Medical Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 05552Q202 (CUSIP Number) Fnu Oudom 4920 Silve |
|
| August 2, 2022 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Amendment No. 1 (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13D-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13D-2(a) BIMI International Medical Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 05552Q202 (CUSIP Number) Tiewei Song 9th Floor, Building 2, Chongqing Corpora |
|
| July 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2022 BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) (Comm |
|
| July 21, 2022 |
Amended and Restated Certificate of Incorporation Exhibit 3.1 |
|
| July 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 July 13, 2022 Date of Report (Date of earliest event reported) BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 000-50155 02-0563302 (State or other jurisdiction of incorporation) (Commi |
|
| July 15, 2022 |
BIMI Announces Results of 2022 Annual General Meeting of Stockholders Exhibit 99.1 BIMI Announces Results of 2022 Annual General Meeting of Stockholders New York, July 15, 2022 (GLOBE NEWSWIRE) - BIMI International Medical Inc. (NASDAQ: BIMI) (?BIMI? or the ?Company?), a healthcare products and services provider, today announced the results of the Company?s 2022 Annual General Meeting of Stockholders (the ?Annual Meeting?) held on July 13, 2022 at 11:00 a.m. (Beijin |
|
| July 15, 2022 |
Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2022 BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) (Comm |
|
| July 7, 2022 |
Stock Purchase Agreement dated July 5,2022 Exhibit 4.1 STOCK PURCHASE AGREEMENT AMONG BIMI International medical Inc., AS BUYER, Phenix bio inc., AS THE COMPANY, AND fnu oudom, AS SELLER. DATED July 5, 2022 STOCK PURCHASE AGREEMENT THIS STOCK PURCHASE AGREEMENT (this ?Agreement?) is made as of July 5, 2022 by and among BIMI International Medical, Inc., a company organized under the laws of the state of Delaware (?Buyer?), Phenix bio inc., |
|
| July 7, 2022 |
Exhibit 99.1 BIMI Enters into Definitive Agreement to Acquire Phenix Bio Inc. Transaction expected to expand business and fuel growth New York, July 07, 2022 (GLOBE NEWSWIRE) - BIMI International Medical Inc. (NASDAQ: BIMI) (?BIMI? or the ?Company?), a healthcare products and services provider, today announced that on July 5, 2022, the Company entered into a definitive stock purchase agreement (th |
|
| July 7, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 5, 2022 BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) (Commi |
|
| June 21, 2022 |
Amendment to Executive Employment Agreement dated June 9, 2022. Exhibit 99.1 AMENDMENT to executive employment AGREEMENT This Amendment To Executive Employment Agreement (this “Agreement”) is made and entered into as of June 9, 2022 by and between BIMI INTERNATIONAL MEDICAL INC., a Delaware corporation (the “Company”) and Tiewei Song (“Executive”).” Each of the parties named above may be referred to herein as a “Party” and collectively as the “Parties.” RECITA |
|
| June 21, 2022 |
US05552Q2021 / BIMI INTERNATIONAL MEDICAL INC / Tiewei Song - SCHEDULE 13D Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13D-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13D-2(a) BIMI International Medical Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 05552Q202 (CUSIP Number) Tiewei Song 9th Floor, Building 2, Chongqing Corporation Avenue, Yuz |
|
| June 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2) ? Definitive Proxy Statem |
|
| June 16, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2022 BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) (Comm |
|
| June 10, 2022 |
Amendment to Executive Employment Agreement dated June 9, 2022 Exhibit 4.3 AMENDMENT to executive employment AGREEMENT This Amendment To Executive Employment Agreement (this ?Agreement?) is made and entered into as of June 9, 2022 by and between BIMI INTERNATIONAL MEDICAL INC., a Delaware corporation (the ?Company?) and Tiewei Song (?Executive?).? Each of the parties named above may be referred to herein as a ?Party? and collectively as the ?Parties.? RECITAL |
|
| June 10, 2022 |
Subordinated Promissory Note dated June 9, 2022 Exhibit 4.2 THIS NOTE AND ANY SECURITIES ISSUABLE PURSUANT HERETO HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER THE ACT OR, SUBJECT TO THE TERMS SET FORTH IN THIS NOTE, IN THE OPINION OF COUNSEL IN FORM AND SUBSTANCE REASONABLY SATISFACTORY TO THE IS |
|
| June 10, 2022 |
Stock Purchase Agreement dated June 9,2022 Exhibit 4.1 STOCK PURCHASE AGREEMENT between BIMI MEDICAL INTERNATIONAL INC. and FNU OUDOM dated as of June 9, 2022 STOCK PURCHASE AGREEMENT This Stock Purchase Agreement (this ?Agreement?), dated as of June 9, 2022, is entered into by and between BIMI Medical International Inc., a Delaware corporation (the ?Company?), and Fnu Oudom, a citizen of Vanuatu (the ?Buyer?). RECITALS WHEREAS, the Compan |
|
| June 10, 2022 |
PRE 14A 1 pre14a0622bimiinternational.htm PRELIMINARY PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commi |
|
| June 10, 2022 |
BIMI Announces Entering into a $5 million Stock Purchase Agreement Exhibit 99.1 BIMI Announces Entering into a $5 million Stock Purchase Agreement NEW YORK, June. 10, 2022- BIMI International Medical Inc. (NASDAQ: BIMI) (?BIMI? or the ?Company?), a healthcare products and services provider, today announced that on June 9, 2022, the Company entered into a Stock Purchase Agreement with Mr. Fnu Oudom, the Chairman of the Board of the Company, for the sale of 12,500, |
|
| June 10, 2022 |
Form of Waiver and Consent Agreement Exhibit 4.4 WAIVER AND CONSENT AGREEMENT This Waiver and Consent (the ?Waiver and Consent?) is made and entered into as of June 9, 2022, by and between BIMI International Medical Inc., a Delaware corporation (the ?Company?), and , a Company (the ?Investor?). Capitalized terms used and not otherwise defined herein shall have the meanings set forth for such terms in the November Purchase Agreement ( |
|
| June 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2022 BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) (Commi |
|
| June 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 28, 2022 BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) (Commi |
|
| June 1, 2022 |
Exhibit 3 Amended and restated BY-LAWS OF BIMI international medical Inc. A Delaware Corporation ARTICLE I OFFICES Section 1.01 Registered Office. The registered office of BIMI International Medical Inc. (the ?Corporation?) will be fixed in the Certificate of Incorporation of the Corporation, as the same may be amended and/or restated from time to time (the ?Certificate of Incorporation?). Section |
|
| May 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 May 20, 2022 Date of Report (Date of earliest event reported) BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 000-50155 02-0563302 (State or other jurisdiction of incorporation) (Commis |
|
| May 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50155 BIMI International M |
|
| May 20, 2022 |
Exhibit 99.1 BIMI International Medical Announces First Quarter 2022 Financial Results NEW YORK, May 20, 2022 - BIMI International Medical Inc. (NASDAQ: BIMI) (?BIMI? or the ?Company?), a healthcare products and services provider, today announced its financial results for the quarter ended March 31, 2022. Revenues for the three months ended March 31, 2022 and 2021 were $5,019,748 and $2,168,004, r |
|
| May 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) (Commi |
|
| May 18, 2022 |
BIMI Announces Appointment of New Chairman and Independent Director Exhibit 99.1 BIMI Announces Appointment of New Chairman and Independent Director NEW YORK, May 18, 2022 (GLOBE NEWSWIRE) - BIMI International Medical Inc. (NASDAQ: BIMI) (?BIMI? or the ?Company?), a healthcare products and services provider, today announced that on May 12, 2022, the Board of Directors of the Company appointed Mr. Fnu Oudom to serve as Chairman of the Board and President of the Com |
|
| May 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: March 31, 2022 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| May 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2022 BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) (Commis |
|
| April 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2022 BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) (Com |
|
| April 18, 2022 |
BIMI INTERNATIONAL MEDICAL, INC. AND ITS SUBSIDIARIES CONSOLIDATED BALANCE SHEETS Exhibit 99.1 BIMI International Medical Inc. Announces Fiscal Year 2021 Financial Results NEW YORK, April 18, 2022 (GLOBE NEWSWIRE) - BIMI International Medical Inc. (NASDAQ: BIMI) (?BIMI? or the ?Company?), a healthcare products and services provider, today announced its financial results for the fiscal year ended December 31, 2021. Revenues for the years ended December 31, 2021 and 2020 were $27 |
|
| April 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended: December 31, 2021 or ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 000-50155 BIMI International Medica |
|
| April 15, 2022 |
Subsidiaries of the Registrant Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT: Name Place of incorporation and kind of legal entity Effective interest held(%) Lasting Wisdom Holdings Limited British Virgin Island, a limited liability company 100 Pukung Limited Hong Kong, a limited liability company 100 Beijing Xinrongxin Industrial Development Co., Ltd. The PRC, a limited liability company 100 Boyi (Liaoning) Technology Co., Ltd T |
|
| April 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: December 31, 2021 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| March 18, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2022 BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) (Com |
|
| March 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 17, 2022 BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) ( |
|
| March 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2022 BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) (Comm |
|
| March 3, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* BIMI International Medical Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 05552Q202 (CUSIP Number) December 31, 2021** (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| February 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| February 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| February 3, 2022 |
Amendment No. 3 to the Stock Purchase Agreement and Settlement Agreement dated February 1, 2022 Exhibit 4.1 AMENDMENT No. 3 to Stock purchase AGREEMENT and settlement Agreement This Amendment No. 3 to Stock Purchase Agreement and Settlement Agreement (this ?Agreement?) is made and entered into as of January , 2022 by and among BIMI INTERNATIONAL MEDICAL INC., a company organized under the laws of the state of Delaware (?Buyer?), and Mr. Yu Xiang, a citizen of the PRC ( ?Seller?). Each of the |
|
| February 3, 2022 |
BIMI Announces Amendment to Stock Purchase Agreement of Chaohu Zhongshan Minimally Invasive Hospital Exhibit 99.1 BIMI Announces Amendment to Stock Purchase Agreement of Chaohu Zhongshan Minimally Invasive Hospital NEW YORK, Feb. 02, 2022 (GLOBE NEWSWIRE) - BIMI International Medical Inc. (NASDAQ: BIMI) (?BIMI? or the ?Company?), a healthcare products and services provider, today announced that on February 1, 2022, the Company entered into an Amendment and Settlement Agreement to amend the Stock |
|
| February 3, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2022 BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) (C |
|
| February 2, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* BIMI International Medical Inc. (formerly known as BOQI International Medical Inc.) (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 05552Q103 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this State |
|
| February 2, 2022 |
BIMI Announces 1-for -5 Reverse Stock Split Exhibit 99.1 BIMI Announces 1-for -5 Reverse Stock Split NEW YORK, Feb. 02, 2022 (GLOBE NEWSWIRE) - BIMI International Medical Inc. (NASDAQ: BIMI) (?BIMI? or the ?Company?), a healthcare products and services provider, today announced a 1-for-5 reverse split of its common stock effective today at 5:00 PM EST. Beginning on February 3, 2022, the Company?s common stock will trade on Nasdaq on a split |
|
| February 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 2, 2022 BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) (C |
|
| January 31, 2022 |
Employment Agreement (Zhong, Baiqun) dated January 27, 2022 Exhibit 10.2 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the ?Agreement?), is entered by and between BIMI International Medical Inc., a Delaware company (the ?Company?) and Baiqun Zhong, an individual (the ?Executive?) effective as of May 21, 2021. Except with respect to the direct employment of the Executive by the Company, the term ?Company? as used herein with respect to all obligations of |
|
| January 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2022 BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) (C |
|
| January 31, 2022 |
Employment Agreement (Wang, Xiaoping) dated January 27, 2022 Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the ?Agreement?), is entered into as of January 27, 2022 by and between BIMI International Medical Inc., a Delaware company (the ?Company?) and Xiaoping Wang, an individual (the ?Executive?) effective as of January 1, 2022. Except with respect to the direct employment of the Executive by the Company, the term ?Company? as used herein wit |
|
| December 22, 2021 |
Stock Purchase Agreement dated December 20, 2021 Exhibit 4.1 STOCK PURCHASE AGREEMENT AMONG BIMI International medical Inc., as parent, BIMI HOspital management (Chongqing) co., ltd., AS BUYER, Bengbu Mali OB-GYN hospital co., ltd., AS THE COMPANy, AND renbao chen, Bengbu Mali OB-GYN hospital, AS SELLERS, DATED December 20, 2021 TABLE OF CONTENTS Page 1. DEFINITIONS 1 2. SALE AND TRANSFER OF SHARES; CLOSING 8 2.1 Shares 8 2.2 Purchase Price 8 2. |
|
| December 22, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2021 BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) ( |
|
| December 22, 2021 |
BIMI International Medical Inc. Signs Stock Purchase Agreement With Bengbu Mali OB-GYN Hospital EX-99.1 3 ea152802ex99-1bimiinter.htm PRESS RELEASE DATED DECEMBER 21, 2021 Exhibit 99.1 BIMI International Medical Inc. Signs Stock Purchase Agreement With Bengbu Mali OB-GYN Hospital NEW YORK, Dec. X, 2021 (GLOBE NEWSWIRE) - BIMI International Medical Inc. (NASDAQ: BIMI) (“BIMI” or the “Company”) today announced that it has signed a stock purchase agreement with Bengbu Mali OB-GYN Hospital (the |
|
| December 17, 2021 |
Amendment No. 2 to Stock Purchase Agreement dated 17, 2021 Exhibit 4.1 AMENDMENT No. 2 to stock purchase AGREEMENT This Amendment No. 2 to Stock Purchase Agreement (this ?Agreement?) is made and entered into as of December 17, 2021 by and among BIMI INTERNATIONAL MEDICAL INC., a company organized under the laws of the state of Delaware, the U.S.A. (?Parent?), BIMAI PHARMACEUTICAL (CHONGQING) CO., LTD., a company organized under the laws of the PRC (?Buyer |
|
| December 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2021 BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) ( |
|
| December 17, 2021 |
Amendment No. 1 to Stock Purchase Agreement Exhibit 4.3 AMENDMENT No. 1 to Stock Purchase AGREEMENT This Amendment No. 1 Stock Purchase Agreement (this ?Agreement?) is made and entered into as of 17, 2021 by and among BIMI INTERNATIONAL MEDICAL INC. (?Parent?), CHONGQING GUANZAN TECHNOLOGY CO., LTD. (?Buyer?), CHONGQING ZHUODA PHARMACEUTICAL CO., LTD. (?Zhuoda?), XIAOLIN LIU (?Liu?), XUSEN HE (?He?) and DONG ZHANG (?Zhang?, together with Li |
|
| December 17, 2021 |
Amendment No. 2 to Stock Purchase Agreement dated 17, 2021 Exhibit 4.2 AMENDMENT No. 2 to Stock purchase AGREEMENT This Amendment No. 2 to Stock Purchase Agreement (this ?Agreement?) is made and entered into as of December 17, 2021 by and among BIMI INTERNATIONAL MEDICAL INC., a company organized under the laws of the state of Delaware (?Buyer?), CHAOHU ZHONGSHAN MINIMALLY INVASIVE HOSPITAL, a company organized under the laws of the PRC (?Zhongshan?) and |
|
| December 9, 2021 |
Form of Board of Directors Agreement between the Company and Independent Directors Exhibit 10.1 Board of DIRECTORs AGREEMENT This Board of Directors Agreement (?Agreement?) made effective as December 6, 2021, by and between BIMI International Medical Inc., with its principal place of business at 9th Floor, Building 2, Chongqing Corporation Avenue, Yuzhong District, Chongqing, P.R.China (the ?Company?) and , with an address at (?Director?), provides for director services, accordi |
|
| December 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2021 BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) (C |
|
| December 6, 2021 |
Exhibit 99.1 THE FINANCIAL STATEMENTS OF CHONGQING ZHUODA PHARMACEUTICAL CO., LTD TABLE OF FINANCIAL STATEMENTS Report of Independent Registered Public Accounting Firm F-1 Financial Statements: Balance Sheets F-2 Statements of Operations and Comprehensive Income F-3 Statements of Changes in Stockholders? Equity F-4 Statements of Cash Flows F-5 Notes to Financial Statements F-6 to F-16 Report of In |
|
| December 6, 2021 |
UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION Exhibit 99.2 UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION The acquisition by BIMI International Medical Inc (?BIMI?or ?the Company?) of Chongqing Zhuoda Pharmaceutical Co., LTD (?Zhuoda?), a company organized under the laws of the People?s Republic of China (?the ?PRC?), closed on October 8,2021. On September 10, 2021, the Company entered into a stock purchase agreement to acquire Zhuoda (th |
|
| December 6, 2021 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 8, 2021 BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction o |
|
| November 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2021 BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) ( |
|
| November 19, 2021 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2021 BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction |
|
| November 18, 2021 |
Form of Warrant dated November 2021 Exhibit 10.3 [FORM OF WARRANT] NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRAT |
|
| November 18, 2021 |
Form of Registration Rights Agreement dated November 2021 Exhibit 10.4 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this ?Agreement?), dated as of November 2021, is by and among BIMI International Medical Inc., a Delaware corporation with offices located at 9th Floor, Building 2, Chongqing Corporation Avenue, Yuzhong District, Chongqing, P. R. China, 116000 (the ?Company?), and the undersigned buyers (each, a ?Buyer,? and collectivel |
|
| November 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2021 BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) ( |
|
| November 18, 2021 |
BIMI International Medical Inc. Announces Pricing of $7.8 million Private Placement Exhibit 99.1 BIMI International Medical Inc. Announces Pricing of $7.8 million Private Placement New York, Nov. 18, 2021 (GLOBE NEWSWIRE) - BIMI International Medical Inc. (NASDAQ: BIMI) (?BIMI? or the ?Company?), a healthcare products and services provider, today announced that it has entered into a Securities Purchase Agreement (the ?SPA?) with two institutional investors (the ?Holders?) to sell |
|
| November 18, 2021 |
Form of Securities Purchase Agreement. EX-10.1 2 ea150981ex10-1bimiinter.htm FORM OF SECURITIES PURCHASE AGREEMENT Exhibit 10.1 EXECUTION COPY SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of November 17, 2021, is by and among BIMI International Medical Inc., a Delaware corporation with offices located at 9th Floor, Building 2, Chongqing Corporation Avenue, Yuzhong District, Chongqing, P. |
|
| November 18, 2021 |
Form of Secured Convertible Promissory Note dated November 2021 Exhibit 10.2 [FORM OF SENIOR CONVERTIBLE NOTE] NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFF |
|
| November 15, 2021 |
BIMI International Medical Inc. Announces Third Quarter 2021 Financial Results Exhibit 99.1 BIMI International Medical Inc. Announces Third Quarter 2021 Financial Results NEW YORK, Nov. 15, 2021 (GLOBE NEWSWIRE) - BIMI International Medical Inc. (NASDAQ: BIMI) (?BIMI? or the ?Company?), a leading healthcare products and services provider, today announced its unaudited financial results for the third quarter ended September 30, 2021. Third Quarter 2021 Highlights: ? Revenues. |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50155 BIMI Internation |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2021 BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) ( |
|
| November 12, 2021 |
Unregistered Sales of Equity Securities, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 27, 2021 BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) (Co |
|
| November 8, 2021 |
Press release dated November 8, 2021 Exhibit 10.1 BIMI International Medical Inc. Announces Results of Special Meeting NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) - BIMI International Medical Inc. (NASDAQ: BIMI) (?BIMI? or the ?Company?), a leading healthcare products and services provider, today announced that shareholders have approved the two proposals voted on at the Registrant?s special meeting of shareholders held on November 5, 2 |
|
| November 8, 2021 |
Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2021 BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) (C |
|
| November 1, 2021 |
Executive Employment Agreement (Song, Tiewei) dated October 28, 2021 Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (?Agreement?) is entered into as of October 28, 2021 by and between Song Tiewei (?Executive?) and BIMI International Medical Inc., a Delaware corporation (the ?Company?), effective as of the Effective Date. Certain capitalized terms in this Agreement have the meanings set forth in Appendix A attached to this Agreement, |
|
| November 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2021 BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) (C |
|
| October 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 8, 2021 BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) (Co |
|
| October 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2) ? Definitive Proxy Statem |
|
| October 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2021 BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 001-34890 02-0563302 (State or other jurisdiction of incorporation) |
|
| September 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2) ? Definitive Proxy Statem |
|
| September 14, 2021 |
Stock Purchase Agreement dated September 10, 2021 Exhibit 4.1 STOCK PURCHASE AGREEMENT AMONG BIMI International medical Inc., as parent, Chongqing Guanzan Technology Co., Ltd., AS BUYER, Chongqing zhuoda pharmaceutical co., ltd., AS THE COMPANy, AND XIAOLIN LIU, xusen he and dong zhang, AS SELLERS, DATED September [ ], 2021 TABLE OF CONTENTS Page 1. DEFINITIONS 1 2. SALE AND TRANSFER OF SHARES; CLOSING 7 2.1 Shares 7 2.2 Purchase Price 7 2.3 Paym |
|
| September 14, 2021 |
Entry into a Material Definitive Agreement, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 September 10, 2021 Date of Report (Date of earliest event reported) BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 000-50155 02-0563302 (State or other jurisdiction of incorporation) ( |
|
| September 14, 2021 |
Exhibit 99.1 BIMI International Medical Inc. Signs Stock Purchase Agreement to Acquire Chongqing Zhuoda Pharmaceutical Co., Ltd. NEW YORK, September 14, 2021 (GLOBE NEWSWIRE) - BIMI International Medical Inc. (NASDAQ: BIMI) (?BIMI? or the ?Company?), a leading healthcare products and services provider in China, today announced that it entered into a Stock Purchase Agreement (the ?Agreement?) on Se |
|
| August 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50155 BIMI International Me |
|
| July 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 May 6, 2021 Date of Report (Date of earliest event reported) BIMI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 000-50155 02-0563302 (State or other jurisdiction of inc |
|
| July 20, 2021 |
UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION Exhibit 99.2 UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION The acquisition by BIMI International Medical Inc. (the ?Company?) of YUNNAN YUXI MINKANG HOSPITAL CO., LTD, WUZHOU QIANGSHEN HOSPITAL CO., LTD and SUZHOU EURASIA HOSPITAL CO., LTD (the Target Group), three companies organized under the laws of the People?s Republic of China (?China? or the ?PRC?), closed on May 17, 2021, May 17, 2021 |
|
| July 20, 2021 |
Exhibit 99.1 THE AUDITED COMBINED FINANCIAL STATEMENTS OF MINKANG HOSPITAL, QIANGSHENG HOSPITAL AND EURASIA HOSPITAL AS OF AND FOR THE YEARS ENDED DECEMBER 31, 2020, 2019 AND 2018 TABLE OF FINANCIAL STATEMENTS Report of Independent Registered Public Accounting Firm F-1 Financial Statements: Combined Balance Sheets F-2 Combined Statements of Operations and Comprehensive Income F-3 Combined Statemen |
|
| July 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 July 15, 2021 Date of Report (Date of earliest event reported) BIMI international medical inc. (Exact name of registrant as specified in its charter) Delaware 000-50155 02-0563302 (State or other jurisdiction of incorporation) (Commi |
|
| July 19, 2021 |
Employment Agreement dated July 15 Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the ?Agreement?), is entered into as of July 15th, 2021 (the ?Effective Date?), by and between BIMI International Medical Inc., a Delaware company (the ?Company?) and Amy Xue, an individual (the ?Executive?). Except with respect to the direct employment of the Executive by the Company, the term ?Company? as used herein with respect to al |
|
| July 19, 2021 |
BIMI International Medical Inc. Announces Appointment of New Chief Financial Officer Exhibit 99.1 BIMI International Medical Inc. Announces Appointment of New Chief Financial Officer NEW YORK, July 19, 2021 (GLOBE NEWSWIRE) - BIMI International Medical Inc. (NASDAQ: BIMI) (?BIMI? or the ?Company?), a leading healthcare products and services provider in China, today announced the appointment of Amy Xue as the Company?s new Chief Financial Officer, effective July 15, 2021. Xue is a |
|
| July 12, 2021 |
BIMI International Medical Inc. 6,770,000 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-257479 PROSPECTUS BIMI International Medical Inc. 6,770,000 Shares of Common Stock This prospectus relates to the resale from time to time of up to 6,770,000 shares of our common stock, $0.001 par value per share (the ?Common Stock?) by the selling shareholders named herein (the ?Selling Shareholders?). These shares of Common Stock offered here |
|
| July 7, 2021 |
As filed with the Securities and Exchange Commission on July 7, 2021 As filed with the Securities and Exchange Commission on July 7, 2021 Registration No. |
|
| July 7, 2021 |
July 7, 2021 VIA EDGAR Dale Welcome, Esq. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: BIMI International Medical Inc. Registration Statement on Form S-1 File No. 333-257479 Dear Mr. Welcome: The undersigned, on behalf of BIMI International Medical Inc.. (?BIMI?), issuer of the securities covered by the above-referenced Registrati |
|
| June 28, 2021 |
As filed with the Securities and Exchange Commission on June 28, 2021 Registration No. |
|
| June 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 June 21, 2021 Date of Report (Date of earliest event reported) BIMI INTERNATIONAL MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-50155 02-0563302 (State or other jurisdiction of incorporation) (Commi |
|
| June 25, 2021 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO CERTIFICATE OF INCORPORATION OF BOQI INTERNATIONAL MEDICAL INC. BOQI INTERNATIONAL MEDICAL INC. (the ?Corporation?), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify as follows: 1. The name of the Corporation is BOQI International Medical Inc. The Certificate of Incorporatio |
|
| June 16, 2021 |
BOQI International Medical Inc. Announces Results of 2021 Annual General Meeting of Stockholders Exhibit 99.1 BOQI International Medical Inc. Announces Results of 2021 Annual General Meeting of Stockholders NEW YORK, June 15, 2021 (GLOBE NEWSWIRE) - BOQI International Medical Inc. (NASDAQ: BIMI) (?BIMI? or the ?Company?), a leading healthcare products and services provider in China, today announced the results of the Company?s 2021 Annual General Meeting of Stockholders (the ?Annual Meeting?) |
|
| June 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 June 15, 2021 Date of Report (Date of earliest event reported) BOQI international medical inc. (Exact name of registrant as specified in its charter) Delaware 000-50155 02-0563302 (State or other jurisdiction of incorporation) (Commi |
|
| June 16, 2021 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 June 15, 2021 Date of Report (Date of earliest event reported) BOQI international medical inc. (Exact name of registrant as specified in its charter) Delaware 000-50155 02-0563302 (State or other jurisdiction of incorporation) (Commi |
|
| June 2, 2021 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 February 5, 2021 Date of Report (Date of earliest event reported) BOQI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 000-50155 02-0563302 (State or other jurisdiction o |
|
| June 2, 2021 |
Exhibit 99.1 THE AUDITED COMBINED FINANCIAL STATEMENTS OF GUOYITANG AS OF AND FOR THE YEARS ENDED DECEMBER 31, 2020 AND 2019 TABLE OF FINANCIAL STATEMENTS Report of Independent Registered Public Accounting Firm F-1 Combined Financial Statements: Combined Balance Sheets F-2 Combined Statements of Operations and Comprehensive Income F-3 Combined Statements of Equity F-4 Combined Statements of Cash F |
|
| June 2, 2021 |
UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION Exhibit 99.2 UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION The acquisition by BOQI International Medical Inc. (the ?Company?) of Chongqing Guoyitang Hospital Co., Ltd. (?Guoyitang?), a company organized under the laws of the People?s Republic of China (?China? or the ?PRC?), closed on February 2, 2021. On December 9, 2020, the Company entered into a stock purchase agreement (the ?Guoyitang SP |
|
| June 2, 2021 |
THE AUDITED COMBINED FINANCIAL STATEMENTS OF ZHONGSHAN HOSPITAL AS OF AND FOR THE YEARS ENDED DECEMBER 31, 2020,2019 AND 2018 Exhibit 99. |
|
| June 2, 2021 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 February 2, 2021 Date of Report (Date of earliest event reported) BOQI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 000-50155 02-0563302 (State or other jurisdiction o |
|
| June 2, 2021 |
UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION Exhibit 99.2 UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION The acquisition by BOQI International Medical Inc. (the ?Company?) of Chaohu Zhongshan Minimally Invasive Hospital (?Zhongshan Hospital?), a company organized under the laws of the People?s Republic of China (?China? or the ?PRC?), closed on February 5, 2021. On December 15, 2020, the Company entered into a stock purchase agreement (t |
|
| May 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 May 20, 2021 Date of Report (Date of earliest event reported) BOQI international medical inc. (Exact name of registrant as specified in its charter) Delaware 000-50155 02-0563302 (State or other jurisdiction of incorporation) (Commis |
|
| May 24, 2021 |
Exhibit 99.1 BOQI International Medical Announces First Quarter 2021 Financial Results NEW YORK, May 24, 2021 (GLOBE NEWSWIRE) - BOQI International Medical Inc. (NASDAQ: BIMI) (?BIMI? or the ?Company?), a leading healthcare products and services provider in China, today announced its financial results for the first quarter ended March 31, 2021. First Quarter 2021 Financial Highlights ? Revenues gr |
|
| May 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50155 BOQI International M |
|
| May 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 May 24, 2021 Date of Report (Date of earliest event reported) BOQI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 000-50155 02-0563302 (State or other jurisdiction of incorporation) (Commis |
|
| May 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: March 31, 2021 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| May 12, 2021 |
Exhibit 99.1 BOQI International Medical Inc. Announces Closing of the Acquisition of Wuzhou Qiangsheng Hospital, Suzhou Eurasia Hospital and Yunan Yuxi Minkang Hospital NEW YORK, May 12, 2021 (GLOBE NEWSWIRE) - BOQI International Medical Inc. (NASDAQ: BIMI) (?BIMI? or the ?Company?), a leading healthcare products and services provider in China, today announced that it had completed the acquisition |
|
| May 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 May 6, 2021 Date of Report (Date of earliest event reported) BOQI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 000-50155 02-0563302 (State or other jurisdiction of incorporation) (Commiss |
|
| May 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant S Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2) S Definitive Proxy Statem |
|
| April 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2) ? Definitive Proxy Statem |
|
| April 22, 2021 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 April 16, 2021 Date of Report (Date of earliest event reported) BOQI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 000-50155 02-0563302 (State or other jurisdiction of incorporation) (Comm |
|
| April 22, 2021 |
Amendment Agreement dated April 16, 2021 Exhibit 4.1 AMENDMENT AGREEMENT This Amendment Agreement (this ?Agreement?) is made and entered into as of April 16, 2021 by and among BOQI INTERNATIONAL MEDICAL INC., a company organized under the laws of the state of Delaware, the U.S.A. (?Parent?), BIMAI PHARMACEUTICAL (CHONGQING) CO., LTD., a company organized under the laws of the PRC (?Buyer?), WUZHOU QIANGSHENG HOSPITAL CO., LTD., a company |
|
| April 13, 2021 |
Other Events, Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 April 9, 2021 Date of Report (Date of earliest event reported) BOQI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 000-50155 02-0563302 (State or other jurisdiction of incorporation) (Commi |
|
| April 13, 2021 |
Stock Purchase Agreement dated April 9, 2021 Exhibit 4.1 STOCK PURCHASE AGREEMENT AMONG BOQI International medical Inc., as parent, Bimai Pharmaceutical (Chongqing) Co., Ltd., AS BUYER, WUZHOU qiangsheng hospital co., ltd., suzhou EURASIA hospital co., ltd. and yunan yuxi minkang hospital co., ltd., AS THE acquired COMPANies, AND jiangjin shen and Zhiwei shen, AS SELLERS, DATED April 9, 2021 TABLE OF CONTENTS Page 1. DEFINITIONS 1 2. SALE AN |
|
| April 13, 2021 |
BOQI International Medical Inc. Enters into SPA to Acquire Three Hospitals Exhibit 99.1 BOQI International Medical Inc. Enters into SPA to Acquire Three Hospitals NEW YORK, April 13, 2021 (GLOBE NEWSWIRE) - BOQI International Medical Inc. (NASDAQ: BIMI) (?BIMI? or the ?Company?), a leading healthcare products and services provider in China, today announced the signing of a stock purchase agreement (the ?SPA?) with two individuals ( the ?Sellers?) on April 09, 2021 to acq |
|
| April 12, 2021 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 April 6, 2021 Date of Report (Date of earliest event reported) BOQI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 000-50155 02-0563302 (State or other jurisdiction of incorporation) (Commi |
|
| April 12, 2021 |
Amendment Agreement dated April 6, 2021 Exhibit 4.1 AMENDMENT AGREEMENT This Amendment Agreement (this ?Agreement?) is made and entered into as of April 6, 2021 by and among BOQI INTERNATIONAL MEDICAL INC., a company organized under the laws of the state of Delaware (?Buyer?), CHONGQING GUOYITANG HOSPITAL CO., LTD., a company organized under the laws of the PRC (?Guoyitang?), Jia Song, an individual residing in the PRC (?Song?), and Nan |
|
| April 12, 2021 |
Amendment Agreement dated April 6, 2021 Exhibit 4.2 AMENDMENT AGREEMENT This Amendment Agreement (this ?Agreement?) is made and entered into as of April 6, 2021 by and among BOQI INTERNATIONAL MEDICAL INC., a company organized under the laws of the state of Delaware (?Buyer?), CHAOHU ZHONGSHAN MINIMALLY INVASIVE HOSPITAL, a company organized under the laws of the PRC (?Zhongshan?) and Mr. Yu Xiang, a citizen of the PRC ( ?Seller?). Each |
|
| April 1, 2021 |
BOQI International Medical Announces Fiscal Year 2020 Financial Results Exhibit 99.1 BOQI International Medical Announces Fiscal Year 2020 Financial Results New York, April 1, 2020 - BOQI International Medical Inc. (NASDAQ: BIMI) (“BIMI” or the “Company”) announced its financial results for the fiscal year ended December 31, 2020. Fiscal Year 2020 Financial Highlights: ● Total revenues of $12,844,902 in the year ended December 31, 2020. ● Gross profit of $2,442,817 in |
|
| April 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 April 1. 2021 Date of Report (Date of earliest event reported) BOQI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 000-50155 02-0563302 (State or other jurisdiction of incorporation) (Commi |
|
| March 31, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended: December 31, 2020 or ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 000-50155 BOQI International Medica |
|
| March 31, 2021 |
Subsidiaries of the Registrant Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Name Place of incorporation and kind of legal entity Effective interest held Lasting Wisdom Holdings Limited (?Lasting?) British Virgin Island, a limited liability company 100 % Pukung Limited (?Pukung?) Hong Kong, a limited liability company 100 % Beijing Xinrongxin Industrial Development Co., Ltd. (?Xinrongxin?) The PRC, a limited liability company 100 |
|
| March 15, 2021 |
Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 March 15. 2021 Date of Report (Date of earliest event reported) BOQI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 000-50155 02-0563302 (State or other jurisdiction of incorporation) (Comm |
|
| March 2, 2021 |
Unregistered Sales of Equity Securities, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 November 30, 2020 Date of Report (Date of earliest event reported) BOQI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 000-50155 02-0563302 (State or other jurisdiction of incorporation) (C |
|
| March 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 February 26, 2021 Date of Report (Date of earliest event reported) BOQI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 000-50155 02-0563302 (State or other jurisdiction of incorporation) (C |
|
| March 1, 2021 |
BOQI International Medical Raised $4.5 Million In A Private Placement of Senior Convertible Notes Exhibit 99.1 BOQI International Medical Raised $4.5 Million In A Private Placement of Senior Convertible Notes NEW YORK, March 01, 2021 (GLOBE NEWSWIRE) - BOQI International Medical Inc. (NASDAQ: BIMI) (“BIMI” or the “Company”) today announced that it closed a private placement of $5,400,00 of its senior convertible notes (the “Convertible Notes”) to two existing institutional investors (the “Inve |
|
| February 24, 2021 |
Entry into a Material Definitive Agreement, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 February 24, 2021 Date of Report (Date of earliest event reported) BOQI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 000-50155 02-0563302 (State or other jurisdiction of incorporation) (C |
|
| February 24, 2021 |
Exhibit 99.1 BOQI International Medical Enters into An Amendment to the Securities Purchase Agreement to Increase the Principal Amount of Senior Convertible Promissory Notes to Be Purchased by Two Institutional Investors NEW YORK, February 24, 2021 (GLOBE NEWSWIRE) - BOQI International Medical Inc. (NASDAQ: BIMI) (“BIMI” or the “Company”) today announces that it has entered into an amendment to th |
|
| February 24, 2021 |
Form of Amendment dated February 24. 2021 Exhibit 4.1 Execution Version AMENDMENT NO. 1 TO SECURITIES PURCHASE AGREEMENT This AMENDMENT NO. 1, dated as of February 24, 2021 (this ?Amendment?), to the SECURITIES PURCHASE AGREEMENT (the ?Securities Purchase Agreement?), dated as of May 18, 2020, by and among BOQI International Medical Inc., a Delaware corporation with offices located at Room 3601, Building A, Harbour View Place, No. 2 Wuwu |
|
| February 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 February 5, 2021 Date of Report (Date of earliest event reported) BOQI International Medical Inc. (Exact name of registrant as specified in its charter) Delaware 000-50155 02-0563302 (State or other jurisdiction of incorporation) (Co |
|
| February 10, 2021 |
Exhibit 99.1 BOQI International Medical Announces Closing of the Acquisition of Chaohu Zhongshan Minimally Invasive Hospital New York, Feb. 09, 2021 (GLOBE NEWSWIRE) - BOQI International Medical Inc. (NASDAQ: BIMI) (“BIMI” or the “Company”) today announced that it had completed the acquisition of Chaohu Zhongshan Minimally Invasive Hospital (“Zhongshan Hospital”). Pursuant to the acquisition agree |
